Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Emergent BioSolutions has received an award to supply 44.75 million doses of BioThrax (Anthrax Vaccine Adsorbed) to the US government over a period of five years for about $1.25bn.
Subscribe to our email newsletter
BioThrax vaccine is licensed by the US Food and Drug Administration (FDA) to protect against anthrax infection.
Under this award, the initial deliveries are likely to begin in 2011 with 8.5 million doses scheduled to be delivered during the first contract year.
Deliveries are scheduled to continue, subject to availability of funding, through September 2016.
Emergent BioSolutions chairman and CEO Fuad El-Hibri said the 5-year award provides for uninterrupted supply of this critical biodefense countermeasure while addressing the government’s mandate to reduce spending across all programs.
"In coming to agreement, Emergent and the Centers for Disease Control and Prevention worked diligently to establish business terms that incorporate substantial price concessions," El-Hibri added.